Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

319 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group.
Kamat AM, Apolo AB, Babjuk M, Bivalacqua TJ, Black PC, Buckley R, Campbell MT, Compérat E, Efstathiou JA, Grivas P, Gupta S, Kurtz NJ, Lamm D, Lerner SP, Li R, McConkey DJ, Palou Redorta J, Powles T, Psutka SP, Shore N, Steinberg GD, Sylvester R, Witjes JA, Galsky MD. Kamat AM, et al. Among authors: lerner sp. J Clin Oncol. 2023 Dec 10;41(35):5437-5447. doi: 10.1200/JCO.23.00307. Epub 2023 Oct 4. J Clin Oncol. 2023. PMID: 37793077 Free PMC article.
Novel agents for muscle-invasive and advanced urothelial cancer.
Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Sonpavde G, et al. Among authors: lerner sp. BJU Int. 2008 Apr;101(8):937-43. doi: 10.1111/j.1464-410X.2007.07326.x. Epub 2007 Nov 13. BJU Int. 2008. PMID: 18005203 Review.
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin S, Kamat A, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP 3rd, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Sabichi AL, et al. Among authors: lerner sp. Clin Cancer Res. 2008 Jan 1;14(1):224-9. doi: 10.1158/1078-0432.CCR-07-0733. Clin Cancer Res. 2008. PMID: 18172274 Clinical Trial.
BCAN Think Tank session 3: Prevention of bladder cancer.
Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. Lerner SP, et al. Urol Oncol. 2010 May-Jun;28(3):338-42. doi: 10.1016/j.urolonc.2009.06.018. Urol Oncol. 2010. PMID: 20439034
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status.
Stadler WM, Lerner SP, Groshen S, Stein JP, Shi SR, Raghavan D, Esrig D, Steinberg G, Wood D, Klotz L, Hall C, Skinner DG, Cote RJ. Stadler WM, et al. Among authors: lerner sp. J Clin Oncol. 2011 Sep 1;29(25):3443-9. doi: 10.1200/JCO.2010.34.4028. Epub 2011 Aug 1. J Clin Oncol. 2011. PMID: 21810677 Free PMC article. Clinical Trial.
319 results